Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Recherches "plusieurs pathologies" ALCINA 2 Analysis of Circulating Tumor Markers in Blood Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCINA-4 (IC 2020-11) Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCYTA (IC 2020-12) Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA Paris, Saint-Cloud NICOLAS GIRARD, NICOLAS GIRARD
Mélanome uvéal et tumeurs oculaires PLUME A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients Paris MANUEL RODRIGUES
Appareil Digestif ProActIF-01 ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers Paris, Saint-Cloud
Recherches "plusieurs pathologies" TG4001.12 A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) Paris CHRISTOPHE LE TOURNEAU
Appareil Digestif ADAGE - Prodige 34 Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over. Saint-Cloud
Appareil Digestif AMEBICA - Prodige 38 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours. Saint-Cloud
Appareil Digestif IROCAS - PRODIGE 52 A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting Saint-Cloud